Title:
IMMUNE CHECKPOINT INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2020/149258
Kind Code:
A1
Abstract:
Provided is a new immune checkpoint inhibitor. The present invention provides an immune checkpoint inhibitor having as an active ingredient one or more selected from a peptide fragment of the N-end region of caveolin 1, a peptide fragment of a scaffolding domain sequence of caveolin 1, a peptide fragment with the scaffolding domain deleted from the N-end region of caveolin 1, a peptide fragment of the caveolin 1 binding region of CD26, and fusion proteins of any of these peptide fragments and an immunoglobulin constant region.
Inventors:
OHNUMA KEI (JP)
MORIMOTO CHIKAO (JP)
HATANO RYO (JP)
MORIMOTO CHIKAO (JP)
HATANO RYO (JP)
Application Number:
PCT/JP2020/000874
Publication Date:
July 23, 2020
Filing Date:
January 14, 2020
Export Citation:
Assignee:
JUNTENDO EDUCATIONAL FOUND (JP)
International Classes:
A61K39/395; A61K38/08; A61K38/10; A61K38/16; A61K38/17; A61K47/55; A61K47/64; A61P35/00; A61P37/06; A61P43/00; C07K11/00; C07K14/47; C07K14/705
Foreign References:
| JP2005503321A | 2005-02-03 | |||
| JP2016069314A | 2016-05-09 |
Other References:
OHNUMA KEI ET AL.: "Blockade of CD 26-mediated T cell costimulation with soluble caveolin-l-Ig fusion protein induces anergy in CD 4+T calls", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 386, 2009, pages 327 - 332, XP026251909, DOI: 10.1016/j.bbrc.2009.06.027
MORIMOTO, CHIKAO; OHNUMA, KEI: "Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY, vol. 43, no. 7, 2016, pages 855 - 862, XP009522623, ISSN: 0385-0684
MORIMOTO, CHIKAO; OHNUMA, KEI: "Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY, vol. 43, no. 7, 2016, pages 855 - 862, XP009522623, ISSN: 0385-0684
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Download PDF: